Novo Nordisk AS

NOV

Company Profile

  • Business description

    With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

  • Contact

    Novo Alle 1
    Bagsvaerd2880
    DNK

    T: +45 44448888

    E: [email protected]

    https://www.novonordisk.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    77,406

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.7048.800.56%
CAC 407,902.2523.790.30%
DAX 4024,456.8192.75-0.38%
Dow JONES (US)44,705.19246.890.56%
FTSE 1008,975.66108.641.23%
HKSE24,028.37136.050.57%
NASDAQ20,646.3635.030.17%
Nikkei 22539,646.36174.92-0.44%
NZX 50 Index12,760.208.41-0.07%
S&P 5006,285.1921.930.35%
S&P/ASX 2008,589.2050.600.59%
SSE Composite Index3,509.6816.630.48%

Market Movers